LakeShore Biopharma Co Ltd
LSB0.720USD
-0.017-2.28%
Market hours （ET）Quotes delayed by 15 min
13.74MMarket Cap
--P/E TTM
More Details of LakeShore Biopharma Co Ltd Company
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Company Info
Ticker SymbolLSB
Company nameLakeShore Biopharma Co Ltd
IPO dateJul 30, 2021
CEOMr. Dave Chenn
Number of employees758
Security typeOrdinary Share
Fiscal year-endJul 30
Address- -
City- -
Stock exchangeNASDAQ Capital Market Consolidated
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolLSB
IPO dateJul 30, 2021
CEOMr. Dave Chenn
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
Shareholders
Shareholders
Proportion
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
Shareholder Types
Shareholders
Proportion
Corporation
65.09%
Individual Investor
13.80%
Research Firm
2.54%
Investment Advisor
0.35%
Private Equity
0.34%
Investment Advisor/Hedge Fund
0.26%
Hedge Fund
0.03%
Other
17.60%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
28
16.97M
69.54%
+11.17M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
2023Q1
71
6.78M
73.08%
+4.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Apex Prospect Ltd
9.84M
51.55%
+9.84M
--
Feb 08, 2024
Zhang (Yi)
4.91M
25.73%
--
--
Feb 16, 2024
TD Securities, Inc.
1.05M
5.49%
+1.05M
--
Mar 31, 2025
Shao (Hui)
313.64K
1.64%
+108.76K
+53.09%
Jun 30, 2024
OrbiMed Advisors, LLC
140.43K
0.74%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
116.51K
0.61%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
75.18K
0.39%
--
--
Mar 31, 2025
Superstring Capital Management LP
30.79K
0.16%
--
--
Mar 31, 2025
Barclays Bank PLC
24.76K
0.13%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Date
Type
Ratio
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
